Kang Zijian, Wang Jing, Huang Wending, Liu Jianmin, Yan Wangjun
Neurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Department of Rheumatology and Immunology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Front Cell Dev Biol. 2022 May 13;10:874429. doi: 10.3389/fcell.2022.874429. eCollection 2022.
Melanoma is one of the most aggressive and heterogeneous life-threatening cancers. However, the heterogeneity of melanoma and its impact on clinical outcomes are largely unknown. In the present study, intra-tumoral heterogeneity of melanoma cell subpopulations was explored using public single-cell RNA sequencing data. Marker genes, transcription factor regulatory networks, and gene set enrichment analysis were further analyzed. Marker genes of each malignant cluster were screened to create a prognostic risk score, and a nomogram tool was further generated to predict the prognosis of melanoma patients. It was found that malignant cells were divided into six clusters by different marker genes and biological characteristics in which the cell cycling subset was significantly correlated with unfavorable clinical outcomes, and the Wnt signaling pathway-enriched subset may be correlated with the resistance to immunotherapy. Based on the malignant marker genes, melanoma patients in TCGA datasets were divided into three groups which had different survival rates and immune infiltration states. Five malignant cell markers (PSME2, ARID5A, SERPINE2, GPC3, and S100A11) were selected to generate a prognostic risk score. The risk score was associated with overall survival independent of routine clinicopathologic characteristics. The nomogram tool showed good performance with an area under the curve value of 0.802.
黑色素瘤是最具侵袭性和异质性的危及生命的癌症之一。然而,黑色素瘤的异质性及其对临床结果的影响在很大程度上尚不清楚。在本研究中,利用公开的单细胞RNA测序数据探索了黑色素瘤细胞亚群的肿瘤内异质性。进一步分析了标记基因、转录因子调控网络和基因集富集分析。筛选每个恶性簇的标记基因以创建预后风险评分,并进一步生成列线图工具以预测黑色素瘤患者的预后。研究发现,恶性细胞根据不同的标记基因和生物学特征被分为六个簇,其中细胞周期亚群与不良临床结果显著相关,而富含Wnt信号通路的亚群可能与免疫治疗耐药性相关。基于恶性标记基因,将TCGA数据集中的黑色素瘤患者分为三组,这三组具有不同的生存率和免疫浸润状态。选择五个恶性细胞标记物(PSME2、ARID5A、SERPINE2、GPC3和S100A11)来生成预后风险评分。该风险评分与总生存期相关,独立于常规临床病理特征。列线图工具表现良好,曲线下面积值为0.802。